China Pharmaceutical Market Overview 2015

DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/j892gq/the) has announced the addition of the "The Pharmaceutical Market: China" report to their offering. We remain bullish on China s pharmaceutical sector despite the slowdown in the economy and political reshuffle. Alesse (Levonorgestrel Bp + Ethinylestradiol Bp) without Rx We do not think the reshuffle will have any adverse changes or cause any reversals to healthcare reform given that the country has been rolling out various healthcare schemes and that a key person overseeing these healthcare reform plans is Vice Premier Li Keqiang, the man who may potentially take over from Premier Wen Jiabao in the reshuffle. Buy Zanaflex (Tizanidine) However, the business environment will potentially be threaten by cost- containment policies as the country will have to contain its ever-growing healthcare expenditure. Risk/Reward Rating China continues to rank fourth out of the 18 key markets in Q1 Asia Pacific Pharmaceutical Risk/Reward Ratings with an unchanged score of 62.5 Its high ranking on the table (just behind developed markets Japan, South Korea and Australia) is largely due to the strong growth potential of the pharmaceutical market that is underpinned by a large and increasingly affluent population and an increasing burden of non-communication diseases. Competitive Landscape The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors. Key Topics Covered: 1. About Viagra Pack-90 () with free prescription SWOT 2. About Flutiair with no prescription Political 3. About Inderal (Propranolol) with free Rx Economy 4. Buy Coral Calcium online Operational Risk 5. http://asthmareview.wordpress.com Industry Forecast 6. Pharmaceutical Market Forecast 7. Healthcare Market Forecast 8. Prescription Drug Market Forecast 9. Patented Drug Market Forecast 10. Generic Drug Market Forecast 11. OTC Medicine Market Forecast 12. Pharmaceutical Trade Forecast 13. Key Risks To The Forecast Scenario 14. Macroeconomic Forecasts 15. Economic Activity 16. Industry Risk Reward Index 17. Asia Pacific Risk/Reward Index 18. China Risk/Reward Index 19. Rewards 20. Risks 21. Market Overview 22. Industry Trends And Developments 23. Epidemiology 24. Healthcare Sector 25. Research And Development 26. Clinical Trials 27. Biotechnology Sector 28. Regulatory Development 29. Regulatory Regime 30. Intellectual Property Issues 31. Pricing Regime 32. Reimbursement Regime 33. Competitive Landscape 34. Pharmaceutical Wholesale 35. Recent Developments Companies Mentioned - AstraZeneca - Bayer - China Shijiazhuang Pharmaceutical Group - Eli Lilly - GlaxoSmithKline - Merck & Co - Merck KGaA - North China Pharmaceutical Corporation - Novartis - Pfizer - Roche - Sanofi - Shanghai Pharmaceutical - Sinopharm For more information visit .researchandmarkets.com/research/j892gq/the